Promote early life antiviral immunity via indole-3 propionate Supplementation

Background

The field of pediatric immunology focuses on protecting infants from severe respiratory viral infections, such as respiratory syncytial virus (RSV) and influenza. Infants possess underdeveloped immune systems and experience a rapid decline in maternal antibodies, creating a critical “immunity gap” that leaves them highly vulnerable to respiratory diseases. Furthermore, modern sanitary environments have reduced human microbiome diversity, which historically played a crucial role in shaping early host immunity. Consequently, there is an urgent need for prophylactic strategies that can safely bolster innate mucosal defenses in infants during high-risk viral seasons.

Current clinical strategies, such as vaccines and monoclonal antibodies, face significant limitations in addressing this pediatric vulnerability. These traditional prophylactics are strictly pathogen-specific, providing protection against only a single targeted virus rather than offering broad-spectrum defense. Because they rely on introducing external antibodies or stimulating adaptive immunity, they are highly susceptible to viral mutational escape and resistance. Additionally, these conventional treatments carry potential side effects and face immense regulatory hurdles for pediatric use. Logistically, they are expensive to manufacture, require strict cold-chain storage, and are difficult to distribute globally, limiting their widespread accessibility.

Technology

This technology utilizes indole-3 propionate (IPA), a naturally occurring gut microbiota-derived metabolite, to enhance early-life antiviral immunity against respiratory infections like RSV and influenza. Administered via infant formulas, oral drops, or maternal supplements, IPA crosses the intestinal barrier and acts directly on lung epithelial cells. It activates type I interferon signaling, inducing a dose-dependent increase in critical antiviral proteins such as IFN-β. This mechanism establishes a robust, localized antiviral state in the lungs prior to exposure, effectively reducing viral loads, decreasing inflammation, and preventing disease-related weight loss.

This solution is highly differentiated from traditional prophylactics, such as vaccines and monoclonal antibodies, primarily through its broad-spectrum efficacy. Rather than targeting a single specific pathogen, IPA gently modulates the host’s innate immune system to provide non-specific mucosal readiness against various viruses. Because it relies on a natural metabolic pathway to strengthen host defenses, it carries a highly favorable safety profile and an exceptionally low risk of viral mutational escape or resistance. Furthermore, unlike conventional biologics that require expensive manufacturing and strict cold-chain storage, IPA is cost-effective, highly scalable, and stable at room temperature.

Benefits

• Provides broad-spectrum protection against severe respiratory viral infections, such as RSV and influenza, by enhancing early-life antiviral immunity.
• Reduces viral loads, decreases lung inflammation, and prevents disease-related weight loss during respiratory infections.
• Offers a highly favorable safety profile by utilizing a naturally occurring, microbiota-derived metabolite (IPA) to gently modulate the host’s innate immunity.
• Carries a low risk of viral mutational escape and resistance because it targets host defense mechanisms rather than specific pathogens.
• Eliminates the need for expensive cold-chain storage, offering a cost-effective, highly scalable, and room-temperature stable alternative to traditional biologics.
• Enables versatile and convenient administration through direct integration into infant formulas, oral drops, syrups, or maternal prenatal and postnatal supplements.

Applications

• Antiviral infant formula additive
• Maternal prenatal immune supplements
• Infant seasonal antiviral drops
• Premature infant viral prophylaxis
• Adjunct respiratory antiviral therapy

Additional info

This technology utilizes indole-3 propionate (IPA), a gut microbiota-derived tryptophan metabolite, to boost early-life antiviral immunity. Administered orally to infants (1–100 mg/kg/day) or prenatally to mothers, IPA enters systemic circulation and stimulates lung epithelial cells. This activates type I interferon signaling, increasing antiviral proteins like IFN-β. This broad-spectrum, non-pathogen-specific mechanism strengthens mucosal defenses, reducing viral loads and lung inflammation against respiratory viruses like RSV and influenza.